Eagle Health Investments LP Purchases 64,500 Shares of Icon Plc $ICLR

Eagle Health Investments LP lifted its position in shares of Icon Plc (NASDAQ:ICLR) by 35.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 247,090 shares of the medical research company’s stock after purchasing an additional 64,500 shares during the quarter. Icon accounts for approximately 9.9% of Eagle Health Investments LP’s investment portfolio, making the stock its 2nd largest holding. Eagle Health Investments LP’s holdings in Icon were worth $45,025,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Toth Financial Advisory Corp bought a new position in shares of Icon during the 4th quarter worth approximately $27,000. Ameriflex Group Inc. bought a new position in shares of Icon during the 3rd quarter worth approximately $33,000. Wilmington Savings Fund Society FSB lifted its position in shares of Icon by 153.4% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after buying an additional 201 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Icon during the 3rd quarter worth approximately $63,000. Finally, Johnson Financial Group Inc. bought a new position in shares of Icon during the 3rd quarter worth approximately $71,000. Institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the subject of several analyst reports. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Leerink Partners set a $125.00 price objective on Icon in a research report on Monday, May 4th. BMO Capital Markets upgraded Icon from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $100.00 to $130.00 in a research report on Thursday, March 26th. Royal Bank Of Canada assumed coverage on Icon in a research report on Monday. They issued a “sector perform” rating and a $123.00 price objective for the company. Finally, Bank of America reiterated an “underperform” rating and issued a $75.00 price objective on shares of Icon in a research report on Thursday, February 12th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $145.67.

Icon Trading Up 1.4%

ICLR stock opened at $115.09 on Thursday. The company has a market cap of $9.29 billion, a P/E ratio of 15.57, a PEG ratio of 2.97 and a beta of 1.23. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The business has a fifty day moving average of $110.01 and a 200-day moving average of $143.38.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.